TARS News and Press, Tarsus Pharmaceuticals Inc.

IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Care Conference on Tuesday, March 3 rd , at 11:30 a.m. PT / 2:30 p.m...

2026-02-24 13:47:24 ET I have covered Tarsus Pharmaceuticals ( TARS ) several times, highlighting the company as a Buy due to the robust growth of Xdemvy. Since my first article one year ago, the stock has risen from $47 to $75, a 60% gain that outpaced the S&P 500. In 2026,...

2026-02-24 06:16:17 ET More on Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript Tarsus Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.20 misses by $0.0...

2026-02-24 06:15:02 ET Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call February 23, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript

2026-02-23 18:02:29 ET Image source: The Motley Fool. Feb. 23, 2026, 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-23 16:18:56 ET More on Tarsus Pharmaceuticals, Inc. Seeking Alpha’s Quant Rating on Tarsus Pharmaceuticals, Inc. Historical earnings data for Tarsus Pharmaceuticals, Inc. Financial information for Tarsus Pharmaceuticals, Inc. Read the full ar...

Generated full-year 2025 net product sales of XDEMVY ® of $451.4 million , an increase of more than 150% year-over-year Providing expected XDEMVY peak sales potential of more than $2 billion Extending category-creating leadership with initiation of Phase 2 trial of TP-04...

Controladora Vuela Compania de Aviacion S.A.B. de C.V. American Depositary Shares each representing ten (10) Ordinary Participation Certificates (VLRS) is expected to report $0.25 for Q4 2025 Galapagos NV (GLPG) is expected to report $1 for Q4 2025 Octave Specialty Group Inc. (OSG) is exp...

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “D...

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate upd...